Skip to content
OpenCapital
Get started

Polaryx Therapeutics, Inc. PLYX Operating Loss Carryforwards Valuation Allowance

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M—

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$115.64M—

Returns & leverage

See full
Return on equity-1,209.8%—
Current ratio3.5×—

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLossCarryforwardsValuationAllowance.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's operating loss carryforwards valuation allowance.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's operating loss carryforwards valuation allowance?
Polaryx Therapeutics, Inc. (PLYX) reported operating loss carryforwards valuation allowance of $1.5M in Q4 2025.